Objectives: To assess the long-term efficacy and tolerability of mycophenolate mofetil (MMF) in patients with diffuse cutaneous systemic sclerosis (dcSSc).
INTRODUCTION
Systemic sclerosis (SSc) is a heterogeneous, autoimmune disorder of unknown aetiology, characterized by immune dysregulation, microvascular disease and excess collagen deposition. 1 It can result in organ dysfunction, reduced physical function, quality of life and premature mortality. Skin involvement in diffuse cutaneous SSc (dcSSc) can be extensive and result in progressive debility. A variety of immunosuppressive agents have been trialled in SSc, 2 including methotrexate, which has shown modest benefit in two randomized controlled trials for skin manifestations in early dcSSc and is recommended for treatment of dcSSc in the 2008 European League Against Rheumatism (EULAR) recommendations, 3 as well as cyclophosphamide (CYC), which has recently been shown to lead to improvement in interstitial lung disease (ILD) and skin thickening in randomized controlled trials of patients with diffuse or limited SSc. 4 Mycophenolate mofetil (MMF), a lymphocyte antiproliferative agent, exerts its anti-inflammatory effects primarily through the blockade of de novo purine synthesis in B and T lymphocytes. 5 It has also been demonstrated in vivo to down-regulate production of transforming growth factor beta, which is thought to result in reduced deposition of extracellular matrix and hence is a promising therapy in fibrotic disorders. 6 MMF has been associated with improvement in skin thickening in several observational studies in SSc, [7] [8] [9] and more recently, in the Scleroderma Lung Study II (SLS II). 10 This randomized controlled study compared the effect of CYC and MMF on forced vital capacity (FVC) in ILD in patients with diffuse or limited SSc. SLS II demonstrated modest and similar improvements in FVC and modified Rodnan skin score (mRSS) in both treatment groups at 2 years with MMF being better tolerated. 10 Given its more favorable side-effect profile, MMF may be an effective and safer alternative to CYC. In this observational study, we report our practical experience of the use of MMF prescribed primarily for the indication of skin disease. This cohort, derived from the Australian Scleroderma Cohort Study (ASCS) represents one of the largest studies to date of prospectively collected data examining the efficacy and tolerability of MMF therapy in the management of skin disease in dcSSc. Moreover, long-term toxicity and maintenance of effect is assessed in a subgroup of patients treated for up to 5 years with MMF.
MATERIALS AND METHODS

Subjects
Patients were recruited from the ASCS, a prospective, multicentre, longitudinal study of disease outcomes in patients with SSc. These participants are over 18 years of age, fulfill the American College of Rheumatology or Leroy and Medsger criteria for SSc 11, 12 and have given written, informed consent. Patients with dcSSc seen between January 2007 and November 2015 who were treated with MMF for a minimum of 12 months for the indication of skin involvement were identified. Diffuse disease was defined as skin thickening of the proximal limb or trunk and for the purpose of this study, only those patients with a mRSS ≥ 12 were included in line with recent studies. 7 Skin scores were measured and recorded annually and those with a mRSS < 12 at baseline, a primary indication for MMF other than skin, or < 12 months of therapy, were excluded from efficacy analysis. Disease duration was measured from the onset of the first non-Raynaud's symptom. The 
Data collection
Baseline demographics, disease subtype and duration, serology, organ involvement, serial pulmonary function tests, oral aperture, presence of tendon friction rubs, treatment data and mRSS were retrieved from the database. ILD was defined as the presence of interstitial abnormalities on high-resolution computed tomography (CT) scan or lung biopsy and renal crisis as the presence of at least two of the following: new onset hypertension, microangiopathic anemia or rising creatinine. Treating physicians from each centre were contacted to confirm previous and current therapy for skin disease, the dose and indication for MMF therapy as well as adverse effects and reasons for cessation.
The changes in serial mRSS from the date of MMF commencement were analyzed with associated clinical data, censored on 30 November, 2015. The primary outcome was reduction in mRSS. We defined clinically significant improvement in skin thickening as a reduction in mRSS ≥ 5 from baseline as per the EULAR Scleroderma Trials and Research group (EUSTAR) analysis of predictors of improvement in skin fibrosis. 13 Stable disease was defined as a change in mRSS < 5, while clinical deterioration was defined as an increase in mRSS ≥ 5. Further analysis of a subgroup of patients with disease duration < 2 years at time of MMF commencement was performed to assess the impact of shorter disease duration on change in skin scores over time. Change in FVC was analyzed as a measure of response for ILD.
Statistical methods
The mean AE standard deviation was used to describe continuous variables and percentage was used to describe categorical variables. The paired t-test was used to compare mRSS pre-and post-MMF therapy. P-values ≤ 0.05 were considered significant. All statistical analyses were performed using Graphpad Prismâ (GraphPad Software, San Diego, CA, USA).
RESULTS
Study population
Three hundred and eighty-one patients from the ASCS were identified as having diffuse SSc. Of these, 74 were identified as ever having been treated with MMF. Eighteen of these were on MMF for < 12 months and 14 were on MMF for a primary indication other than skin, leaving 42 patients for inclusion in the efficacy analysis ( Table 1 ). The mean age of participants was 53 AE 12 years with 35 (83%) being female. Thirty-four (81%) participants were Caucasian, while seven (17%) were of Asian descent. The mean duration of disease prior to MMF commencement was 4.8 AE 4.3 years, with 21 (50%) participants commencing MMF within 2 years of disease onset.
The vast majority (98%) of the cohort were antinuclear antibody (ANA) positive, with speckled (48%) and homogeneous (43%) patterns being the most prevalent. Seventeen (40%) were anti-topoisomerase antibody positive and 11 (26%) were RNA polymerase III antibody positive. Sixteen (38%) participants had ILD, defined as fibrosis on chest high-resolution CT scan, while three (7%) had a history of renal crisis. The mean mRSS for the entire cohort at baseline prior to MMF commencement was 25.9 AE 9.2. This was not significantly different from those commenced on MMF within 2 years of disease onset, with a baseline mRSS of 27.2 AE 9.6 (P = 0.61). Six patients (14%) had a baseline mRSS ≤ 22.
Compared to a cohort of 339 patients identified from the ASCS who presented with diffuse disease over the study period and who were not commenced on MMF for skin (baseline cohort), the MMF cohort had a shorter disease duration (4.8 AE 4.4 vs. 8.8 AE 8.6 years; P < 0.01), a higher mRSS (25.9 AE 9.2 vs. 20.3 AE 9.9; P < 0.01) and lower FVC (82.6 AE 20.4 vs. 89.5 AE 20.2%; P = 0.04). There was no significant difference between rates of ILD and prevalence of renal crisis.
Therapy
The mean duration of therapy was 2.7 AE 1.7 years with a mean dose of 1.9 AE 0.4 g/day. Twenty-seven (61%) participants had been previously treated with prednisolone, while 19 (45%) were on prednisolone concurrently with MMF therapy. Nineteen (45%) 
Outcome variables
At the censor date, all participants had completed at least 12 months of MMF therapy (n = 42), 28 had been on therapy for at least 2 years (67%), 12 had completed four (29%) and 10 had completed 5 years of therapy (24%; Table 3 ). There was a mean reduction in mRSS of 3.7 AE 7.1 in the first year of therapy, 3.4 AE 6.1 in the second, 1.9 AE 4.6 in the third and 0.9 AE 6.3 after the fourth year. There was a total reduction in mean mRSS of 10.5 AE 10.3 after 5 years of therapy (Fig. 1) .
The improvement in mean mRSS after the second year of therapy as well as each subsequent year was statistically significant. Participants who were commenced on MMF within 2 years of disease onset demonstrated similar reduction in skin scores to the entire cohort, with 1.9 AE 7.1 after the first year of therapy, a further 4.8 AE 5.3 reduction after the second, and a total reduction of 11.4 AE 11.3 by 5 years.
Eighteen (43%) participants achieved clinically significant improvements in skin score after 1 year of MMF therapy. Of those who had been treated for 2 and 4 years or more, this was increased to 61% and 92%, respectively (Fig. 2) . There was no significant difference in baseline mRSS between clinically significant responders and non-responders (P = 0.19). In those commenced on MMF within 2 years of disease onset, 29% and 39% demonstrated clinically significant improvement after 1 and 2 years, respectively, whereas 100% of this subset achieved clinically significant improvement within 4 years of MMF therapy.
There was no significant change in pulmonary function, with mean FVC at study commencement of 82.6 AE 20.4% predicted, compared to a mean FVC of 82.0 AE 20.2% at the end of study (P = 0.74). There was also no significant difference between oral aperture measurement (4.0 AE 0.8 vs. 4.0 AE 0.9 cm; P = 0.92) and the presence of tendon friction rubs (five vs. one patient; P = 0.20) pre-and post-MMF therapy.
Of the 19 patients on concurrent prednisolone, the median daily prednisolone dose on MMF initiation was 5.0 mg (interquartile range [IQR]: 0-10.0) with a significant reduction in median daily dose at censor date to 1.0 mg (IQR: 0-8.7; P < 0.05).
Tolerability
Of the 42 patients treated with MMF, two (5%) ceased therapy due to drug inefficacy after 12 months. Four patients (10%) experienced adverse effects, although this warranted cessation of therapy in two (5%), one 15 The likelihood of progression remains difficult to predict, although short disease duration, synovitis and low baseline skin score (mRSS ≤ 22) have been identified as predictors of an increasing skin score. 16 The heterogeneous nature of the disease as well as the tendency toward spontaneous improvement and reluctance of clinicians to treat with placebo has made it difficult to conduct randomized controlled trials of novel therapies. 17 In this prospective, observational study of 42 patients with diffuse skin disease taking MMF for the primary indication of skin thickening, MMF was associated with modest improvements in skin scores with a fall in mean mRSS of 3.7 at 12 months and 7.6 at 24 months. This concurs with the findings of Mendoza et al., 7 who demonstrated a mean fall in mRSS of 10.9 after 18 months of MMF therapy in 25 patients with early disease (< 2 years), with a reduction in accumulation of fibrotic tissue as well as real-time polymerase chain reaction demonstrating reduced expression of fibrosisrelated genes in skin biopsies. In a larger, retrospective study by Le et al. 9 of 98 patients with a median disease duration of 12.5 months and a baseline mRSS of 23 and a smaller prospective study by Derk et al. 8 of 15 patients with a mean disease duration of 13.4 months and baseline mRSS of 22, skin score reductions of 7.9 and 14, respectively, were seen at 12 months. However, larger doses of MMF up to 3 g were utilized in these studies with potential for greater benefit.
To account for variable patient characteristics and response to therapy, we also determined the number of patients who achieved a significant improvement in mRSS (≥ 5) and found that 43%, 61% and 92% demonstrated improvement in mRSS at 12, 24 and 48 months, respectively. We noted a similar reduction in skin score in those with disease duration < 2 years, although onset of improvement was delayed. This may be explained by the fact that those with shorter disease duration who warrant therapy are more likely to have rapidly progressive disease and are more likely to worsen before any improvement as a result of therapy becomes readily apparent. 16 This is supported by our findings that those with dcSSc who were commenced on MMF for skin disease had a shorter disease duration than those who were not (4.8 AE 4.4 vs. 8.8 AE 8.6 years; P < 0.01). While an mRSS ≤ 22 has been suggested as a predictor of disease progression, 16 this was not able to be meaningfully assessed given the Figure 1 Modified Rodnan skin score (mRSS) over duration of mycophenolate mofetil (MMF) therapy. *P-value reflects mean mRSS from baseline. low proportion of patients with a mRSS ≤ 22 at baseline; however, we did not find a greater improvement in skin scores in those with a higher baseline mRSS.
In the recent SLS II study in which skin scores were examined as a secondary outcome in patients with SSc and ILD, patients with a mean disease duration of 2.5 years were treated for ILD with 2 years of MMF (3 g/day) or 1 year of CYC followed by 1 year of placebo therapy. Compared to preliminary data from the SLS II study, our findings demonstrate a greater reduction in mRSS from baseline at 24 months (7.6 AE 8.1 vs. 4.9 AE 1.0). However, it is worth noting that the SLS II trial included patients with diffuse (56%) and limited SSc (44%), with a lower mean baseline mRSS (15.3 AE 10.4 vs. 25.9 AE 9.2 in our study). Interestingly, this group found a similar percentage of patients with a significant improvement in skin score at 2 years (68% vs. 61%).
Given the lack of a placebo group in our study, we compared the changes in mRSS observed in our study to historical controls from previous randomized controlled trials. Baseline mRSS was not dissimilar to that of a trial of oral bovine type 1 collagen (collagen; 25.9 AE 9.2 vs. 26.1 AE 7.8). 18 However, it was significantly higher than that in the trial of D-penicillamine (D-pen) and the diffuse SSc patients in the SLS I trial of CYC (25.9 AE 9.2 vs. 21.0 AE 8.0 and 20.2 AE 9.3, respectively).
19,20 While we found a reduction of mRSS of 3.7 AE 7.1 at 12 months, these studies reported reductions of 3.4 AE 7.1, 2.5 AE 8.6 and 1.7 AE 6.9, respectively. The D-pen study also reported reduction in mRSS of 4.9 AE 2.7 at 24 months, 17 which is similar to the reduction of 7.8 AE 8.1 we found in our study. Given that duration of these studies was limited to 24 months, we cannot determine whether the ongoing improvement identified in our study up to 5 years of therapy would surpass the degree of improvement in controls from previous studies. However, our study highlights that longer-term studies (up to 5 years) are required to determine the benefits of treatment for skin disease in dcSSc.
Our experience with MMF was not dissimilar to that of Pope et al. 21 and their randomized controlled trial comparing methotrexate to placebo in dcSSc. Their reported reduction in mRSS of 4.1 AE 3.4 after 1 year of therapy was not significantly different from our results of 3.7 AE 7.1. However, our improvement in skin scores are significantly greater than that of the experience of Van den Hoogen et al. 22 who reported a reduction in mRSS of 1.12 AE 6.5 in their cohort of 17 patients after 12 months.
While MMF was commenced primarily for skin thickening, pulmonary function remained stable on therapy. This is in contrast to other studies of MMF in the treatment of SSc-ILD which showed modest improvements in FVC; 7, 8, [23] [24] [25] however, this can be explained by the high baseline FVC in our cohort and the low rates of concurrent, progressive ILD. Oral aperture also remained unchanged over the period of follow-up. While there was a trend to improvement in tendon friction rubs, given the low baseline incidence, this did not reach statistical significance. As has been demonstrated by Fischer et al. in SSc-ILD, 26 we observed a reduction in concurrent use of prednisolone while on MMF therapy.
MMF was well-tolerated, with only 5% ceasing the drug because of adverse events. This is consistent with other studies which have demonstrated superior tolerability of MMF compared to CYC 10 and AZA. 25 Where the high cost of MMF has previously been a barrier to its use in SSc skin disease, the recent introduction of generics may allow easier access to its use in the future.
The strengths of our study include its prospective nature, standardized data collection and the inclusion of patients with only diffuse disease. Although our sample size of 42 is modest, it compares favorably with the number of patients with diffuse disease examined in the SLS II study (n = 38) and Mendoza study (n = 25) and is enriched with 50% of patients with early disease which is more likely to be associated with skin progression. Whereas previous studies have been limited to 2 years of therapy, our study also examined the effect of MMF in a subset of patients up to 5 years with ongoing improvement in skin scores. Whether improvements seen here can be attributable to MMF or reflects the natural regression of the disease remains unclear.
Limitations of our study include its observational nature and the absence of a control group, such that the modest improvement in skin scores in patients treated with MMF in this study may represent the natural improvement in skin disease over time. The mean dose of MMF therapy in our study (1.9 g/day) is also lower than what has been utilized in other SSc trials 10 and higher doses may be associated with a greater response. A larger randomized controlled trial of high-dose MMF for diffuse skin disease will help further elucidate the role of MMF and dosing in dcSSc skin disease.
CONCLUSIONS
In this study, MMF was associated with a modest improvement in skin scores regardless of disease duration and was well-tolerated in the treatment of dcSSc. Given the natural history of dcSSc where skin involvement can spontaneously improve, placebo-controlled studies are required to clarify the role of MMF therapy in dcSSc skin disease.
